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Abstract 
Background:   
The purpose of this research is to assess PMTCT intervention uptake by HIV positive pregnant 
mothers and to assess the degree of linkage to HIV exposed infants to care and treatment 
services in selected. We conducted a prospective observational study in HIV positive pregnant 
mothers and their new-borns attending ANC and PMTCT health services at seven health centers 
in Addis Ababa, Ethiopia. 
Methods:  
Outcome evaluations included retention to PMCTC procedures,  timing of ART initiation, self-
reported ART adherence using a 5-item recall questionnaire, risk factors associated with poor 
treatment adherence, up-take of infant nevirapine prophylaxis, HIV early infant diagnosis (EID) 
procedures and mother-to-child transmission rates.   
Results:  
Of 494 women enrolled into the study 4.9% did not complete PMTCT procedures due to active 
refusal or loss to follow-up. First HIV diagnosis was done in 223 (45.1%) and ART initiated in 321 
(65.0%) women during pregnancy. The median time of ART initiation after HIV diagnosis was 1.3 
weeks (IQR 0-4.3) and 17.4 weeks (IQR 11.7-23.9) before delivery. The majority received triple 
ART, except 37 (7.6%) women starting zidovudine monotherapy following Option A procedures. 
Poor self-reported treatment adherence was higher post-partum as compared to prior delivery 
(12.5% versus 7.0%, p=0.002), and significantly associated with divorced/separated marital 
status (RR 2.2, 95% CI 1.3-3.8), low family income (RR 2.1, 95% CI 1.1-4.1), low CD4 count (RR 
1.7, 95% CI 1.0-3.0), and ART initiation during delivery (RR 2.5, 95% CI 1.1-5.6). Of 435 infants 
born alive 98.6% initiated nevirapine prophylaxis. The mother-to-child HIV transmission rate was 
0.7%, but EID results were received only in 4.8% within 2 months, and cumulatively 46.6% within 
3 months after birth.  
Conclusion: High retention to PMTCT services, triple maternal ART and high uptake of infant 
nevirapine prophylaxis was associated with a low mother-to-child HIV transmission rate. 
Declining post-partum antiretroviral treatment adherence and challenges of EID linkage 
procedures require focused interventions.  
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1. Introduction 
1.1 Global Epidemiology of HIV 
The epidemiological trend of human immunodeficiency virus (HIV) in 2016 is encouraging, with 
the decline of death from HIV/AIDS by 40% since 2000 [1, 2]. According to the UNAIDS global 
report at the end of 2014, 36.9 million people were living with HIV, 2 million people were newly 
infected, and 1.2 million had died from HIV related causes. Since 1990, this is the lowest number 
of new infections that the world has experienced in 20 years. Most importantly, the numbers of 
15-24 years olds that are acquiring HIV infection have declined from 980,000 (930,000-
1,020,000) in 2000 to 620,000 in 2014 [1]. This decline is largely attributed to Sub Saharan Africa 
(SSA) where 41% reduction  was seen in new HIV infections from 2000-2014 [1]. 
Sub-Sahara Africa is the hardest hit region by the epidemic and by the end of 2014 , 25.8 million 
people (70%)  were  living with HIV of which 2.3 million were children < 15 years of age and  58% 
were women [2- 4] . 
In 2014, 1.4 million newly infected adults and children resided in SSA [2]. Children <15 years old 
accounted for an estimate 190,000 of the new infections and 130,000 deaths in 2014 [2].  There 
are regional variations in the severity of the epidemic within Sub- Sharan Africa [5].  The worst 
affected sub region is Southern Africa countries with the highest HIV prevalence among 15-49 
age adults are Swaziland (31%), Lesotho (26.7%), Zimbabwe (17.7%), South Africa (14.1%), 
Mozambique (13.1%) and Malawi (12.9%) [5].    
Data from WHO Africa Region 2013 indicate that women were twice more likely to be infected 
than men in all Sub-Sahara African countries [5], and acquire HIV infection 5-7 years earlier than 
man [4]. Out of the 2.8 million, aged 15-24 that are living with HIV 63% are women [4].  Sex 
differences in HIV prevalence being both biologically and socially determined as  follows:  the 
exposure of the mucosal lining of the vagina  to the concentration of HIV in the semen, cervical 
ectopy in young girls,  gender associated violence, economic empowerment, sexual and 
reproductive health decision making [6,7].  
Reduction of HIV incidence and HIV related mortality rates are mainly due to scale-up of 
antiretroviral therapy (ART).  ART in 2014 was accessed by 10.7 million people as compared to 
100,000 in 2002 [1]. Furthermore, reductions have been attributed to several prevention 
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strategies: behavioral change programs, condoms, HIV Testing, blood supply safety, harm 
reduction efforts for injecting drug users, male circumcision, PMTCT programs, ART treatment, 
pre-exposure antiretroviral prophylaxis (PrEP) for individuals at high risk for HIV infection [1]. 
Global support for the fight against HIV/AIDS has resulted through a multilateral funding 
mechanism and government bilateral support that built a very strong momentum and 
commitment; key players are the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global 
Fund), President’s Plan for Emergency AIDS Relief (PEPFAR), the Bill and Melinda Gates 
Foundation, and the Clinton Foundation.  The Global Fund is one of the largest funders for HIV, 
TB and Malaria programs in low and middle income countries, investing 4 billion year to support 
national and community programs [1].  PEPFAR 2003-2014 has funded 52 billion towards HIV 
Programs and also contributes to the Global Fund. Domestic funding have also increased since 
2000 and in 2014, domestic funding in comprised of 57% of all funding for HIV programs [1]. 
Domestic funding is important in strengthening the ownership and sustainability of HIV 
programs at national level. 
1.2 Prevention of Mother to Child Transmission  
In June 1983 there were first reports of possible mother to child transmission seen in 21 infants 
[9]. Since then numerous cohort studies looked at risk factors that can be associated with 
mother-to-child transmission of HIV and the development of prevention interventions [10-20] 
resulting into  three prevention: 1) reducing maternal viral load with ART; 2) prevention of 
maternal virus at birth through less traumatic obstetric methods (e.g. caesarian sections) 3) 
avoidance of breastfeeding.  These research findings were rapidly translated into policy and 
practice. The fist PMTCT intervention that was made into policy in 1985 by CDC was HIV infected 
women shouldn’t breastfeed but use formula feeding instead [21].  In 1994 the landmark PACTG 
076 study demonstrated a 67% reduction in perinatal HIV transmission with the administration 
of a combination of prenatal, intrapartum and neonatal zidovudine [22]. This regimen was 
rapidly included in the US Public Health Service Guidelines and implemented all over the US 
[23].  In 1999 the results  European Mode of Delivery trial showed  that the rate of MTCT further 
decreased to 1.8%  if a women who received ZDV prophylaxis was also randomized to deliver in 
elective cesarean section versus women who delivered vaginally (10.5%) [24]. PACTG 076 and 
the European Mode of Delivery results furthers decreased  mother to child transmission rate in 
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US and Europe but these regimen were  not implemented in  low and middle income countries 
due to cost and feasibility  [25].     
In an effort to finding a shorter, more feasible, and less expensive ARV treatment in prevention 
mother to child transmission researchers initiated a series of cohort studies in the Americas, 
Europe, Africa, and Asia which eventually translated to policy and WHO Guidelines for 
prevention of mother to child transmission in low and middle income countries [27-32]. 
1.3 Evolution of WHO PMTCT Guidelines 
 The WHO PMTCT Guidelines have been revised 5 times in 13 years based on new evidence from 
clinical trials, program feasibility, and cost implications [33-37]. The first WHO Guideline in 2001 
“Prevention of Mother to Child Transmission of HIV: Selection and Use of Nevirapine” was 
influenced by the HIVNET 012 trial in Uganda [30, 31, 33] which compared single dose 
Nevirapine to the mother at the time of labor and to the infants within 72 hours of birth versus 
ZDV given to the mother during labor and to infants for seven days. The mother to child 
transmission rate in the NVP group at 6-8 weeks was 8.2% and 10.1% at 18 month while  in the 
ZDV group transmission rate were 20% and 25.8%, respectively [30,31]. Following the favorable 
outcome in the NVP groups the Guideline recommended a single oral NVP 200mg dose tablet to 
be taken by the mother at the onset of labor and an oral dose of NVP in suspension (2mg/kg) to 
be given to the newborn within 72 hours of birth (33).  
The efficacy of ZDV plus single dose maternal and infant nevirapine has been examined in 
several clinical trials [26-29, 38].  The Perinatal and HIV Prevention Trial in Thailand in 2004 
showed that a single dose of NVP combined with oral ZDV starting at 28 weeks of gestation to 
the mother and a one week ZDV to the infant reduced mother to child transmission rate to 2% 
[32].  WHO PMTCT Guideline in 2004, adopted this finding and recommended for HIV pregnant 
women with CD4 count < 200cells/µL to initiate triple ART including ZDV, Lamivudine (3TC) 
+NVP or Stavudine (d4T) +3TC+NVP  [34]. Infants that are born to mothers either receiving 1st 
line or 2nd line regimen should be given ZDV, sdNVP, or sdNVP +ZDV for one week. HIV infected 
pregnant mothers who were not in need of ART for their health were recommended to start 
ZDV from 28 weeks until labor, and a sdNVP at the onset of labor, while the  infants were 
treated with single dose  NVP plus ZDV for one week [34]. 
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The third WHO PMTCT Guideline 2006 recommended for women in need for triple ART for their 
own health ZDV+ 3TC+ NVP and for infants ZDV for seven days except if the mother receives less 
than four weeks of ART. In this case infant ZDV prophylaxis was to be given for four weeks. 
Pregnant women not eligible for ART were recommended to start dual ARV prophylaxis of ZDV 
and 3TC from weeks 28 plus sdNVP during delivery [35].  
 
Table 1: Prophylactic Regimen for Pregnant Who do need ART for their own 
Antepartum AZT 300mg twice a day starting at 26 weeks or as soon as possible 
Intrapartum sd-NVP +AZT/3TC 
Post- Partum AZT/3TC for 7 days 
Infants Irrespective of mode of infant feeding sdNVP within 72 hours of delivery + 
AZT for 7 days 
 
The Kesho Bora Study findings strongly influenced the 2010 WHO PMTCT Guideline  [39, 40] and  
compared for the first the safety and efficacy of  triple ART (ZDV+ Lamivudine + 
Lopinavir/Ritonavir) from the last trimester of pregnancy, continued during breastfeeding , up to 
6 month of age against WHO 2004 PMTCT recommended regimen [39,40]. The mother to child 
transmission and the infant mortality rate following the WHO 2006 procedures at 12 month was 
9.5% and 6.5%, respectively, as compared to 5.4% and 4.8% from the intervention [39, 40]. 
These results led to the following implications: 1) initiation of ART early in pregnancy or even 
before pregnancy 2) 80% transmission occur in women with CD4 counts < 350 cell/µ   3) priority 
access to ARV for HIV positive women who plan to get pregnant [39,40]. The WHO 2010 PMTCT 
recommendation resulting from the Kesho Bora study findings are presented in table [36]. The 
recommendation included an option based on maternal single ZDV dose prophylactic treatment 
for those not in needs for ART for their own health (Option A) and a triple ART approach for 
mothers eligible for ART by CD4 counts (Option B). 
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Table 2:  WHO 2010 PMTCT Guidelines 
Option A Option B 
Mother Mother 
Antepartum: AZT from 14 weeks of gestation 
and continued during pregnancy 
Triple ARV prophylaxis from 14 weeks of 
gestation or as soon as feasible 
Intrapartum: sd-NVP +AZT/3TC Triple ARV prophylaxis 
 
Postpartum: AZT/3TC for 7 days 
Triple ARV prophylaxis continued until 1 week 
after infant exposure to breastmilk has ended 
Infant Infant 
For breastfeeding infants: Daily NVP for a 
minimum of 4-6 weeks, and until 1 week after 
exposure to breast milk has ended 
Irrespective of mode of Infant feeding. 
Daily NVP or twice daily AZT from birth until 4 
to 6 weeks of age. 
Infants receiving replacement feeding only 
daily NVP or sd-NVP+ twice –daily AZT until 4-
6weeks of age. 
 
 
In 2011, the Malawian Ministry of Health adopted a pragmatic and ambitious public health 
approach to improve the low PMTCT coverage in Malawi known as “Option B+,” which provides 
all HIV-infected pregnant and breastfeeding women with immediate, lifelong ART, regardless of 
clinical stage or CD4 cell count [41]. By eliminating the complex 2010 PMTCT algorithms, delays 
from CD4 testing, and ART re-initiations with each pregnancy with Option B, Option B+ 
simplified the PMTCT process, with expected important benefits for HIV-infected women, their 
HIV-exposed infants, and their HIV-uninfected sex partners . This translated into the final WHO 
Option B+ PMTCT Guideline for both ART and PMTCT in 2013 [37, 42]. Even though Option A 
and Option B in the 2010 Guideline had similar efficacy in clinical trial settings it has been 
difficult to scale up Option A in low income countries (37, 42). Option B+ was meanwhile 
adopted by most African countries because it is given to all pregnant women and continued 
during pregnancy, labor, and postpartum, the fixed dose regimen TDF+ 3TC+EFV can be given to 
both pregnant and non-pregnant adults, CD4 count is not a requirement for initiation, Option B+ 
delays maternal disease progression, it maximize ART coverage and decrease mother to child 
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transmission, and reduces sexual transmission of HIV to sero-discordant partner (37, 41). In the 
Malawi study where the cost effectiveness of  Option A, Option B and Option B+ was analyzed it 
was shown that Option B+ represented a cost effective  strategy because  it prevented new HIV 
infections but also improved the survival of infants. [43] 
WHO PMTCT Guideline regimens in research clinical trial settings show impressive efficacy but 
translation of these regimens into implementation in low and middle income countries has 
remained a challenge [25, 44] 
 
1.4 PMTCT Update in Sub-Sharan Africa 
PMTCT programs have been implemented in Sub Saharan Africa since early 2000 but  the 
number of newly infected children has only declined by 24% between 2000- 2009 (8). Despite 
the clinical trial findings on efficacious regimens and major initiatives launched to make 
treatment accessible through WHO, GFTAM, PEPFAR, Clinton Foundation and Bill and Melinda 
Gates Foundation, PMTCT programs in SSA have lagged behind [25,44]. Reasons for this are low 
uptake of HIV testing, weak health infrastructures, weak support from the highest level of 
government and public health authorities, home delivery, lack of male involvement, lack of 
family planning, limited donor funding, and PMTCT drug and HIV kit stock outs [25, 44]. 
Overall there has been progress between 2000-2015 in reduction of new HIV infection in 
children and ART coverage for HIV positive women. At the same time there have been 
challenges in the reduction of mother to child transmission, timely early infant diagnosis of HIV, 
ART coverage for children, decreasing the incidence of new HIV infection among women within 
child bearing age, and family planning [8] 
The Global Plan towards the elimination of new HIV infections among children and keeping 
mothers alive in 2011 was launched with key decision makers from 35 countries at the UN to 
address these limitations of PMTCT programs in 21 low and middle income countries which 
account for 90% of the HIV positive children [8].  
The two main targets of the Global Plan are:  
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1. To reduce the number of new childhood infections by 90% by 
I. Reducing AIDS related infant death by >50%. 
II. providing  ARV for all HIV infected Children  
2. Reduce the number of HIV related maternal death by 50%.   
These targets and indicators were each then combined within four WHO pronged approaches 
for PMTCT to create a scaled up and improved PMTCT program with targets that can be 
monitored [8]. The Global Plan main target was to reduce the number of new childhood 
infections by 90% by reducing AIDS related infant death by >50% and by providing ARV for all 
HIV infected children [8].  Since the launch of the Global Plan in 2011, HIV incidence in children 
among the 21 priority countries declined by 76% in South Africa, 60% in Ethiopia , Mozambique, 
Namibia, Swaziland, Uganda, and Tanzania, 40% in Botswana, Ghana, Lesotho, Malawi and 
Zimbabwe [1, 8]. In spite of this progress the identification and ARV treatment of HIV positive 
infants is lagging. WHO recommends that early infant diagnosis is performed within 4-6 weeks 
after birth and the dry blood spot results be returned to the health facility sites within 2 month 
of the infant birth date [45]. In most SSA countries Dry blood spots are taken from the infant at 
health centers and sent to a regional or referral laboratory.  At the laboratory, the dried blood 
spots on the cards are analyzed using DNA- PCR technology. The results are then sent back to all 
the different health centers through a motorcycle courier or SMS. The cascade of events that 
have to take place before the DBS reaches the health facility and linkage of the infant to 
treatment is error prone. The nature of the cascade can have a long waiting period which causes 
mothers not to come back to health facility, delayed initiation to ARV for infant or even failure 
to initiate treatment for infant.  
 In 2014, only 49% of infants in the 21 priority countries had EID testing done within a two 
month period [8]. In a study from South Africa missed opportunities for early infant diagnosis 
included identification of HIV exposed infants by health providers (mothers had to carry Infant 
Health to Chart /booklet for identification), MTCT knowledge, adherence to treatment, and 
discrimination as the main determinant for uptake of EID services  [46]. A study in rural Kenya 
indicated that mothers didn’t know the exact time points, or type of tests required for EID 
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service  [47].  Another study in Uganda found that the average age of infant for first EID was 14 
weeks and the turnaround time of EID results on average was 45 days and 29.5 % of care takers 
didn’t come back for test results [48].  In the same study for second EID test for diagnosis of 
MTCT at 6 month only 39.7 % brought their children back for testing and only 40% of those that 
were tested positive was initiated on ART [48]. 
In an Ethiopian study reasons for mothers not coming back after  the end of breast feeding 
period for EID was the lack of understanding  that mother to child transmission can still take 
place after  breastfeeding period even if  the 6 weeks DBS result was negative [49]. The failure 
to identify HIV positive infants  through EID and initiate ART  timely causes high rate of 
mortality, development of immunodeficiency syndrome, encephalopathy and 
neurodevelopmental effects [50-52].  Among the 21 priority countries only 31% of children are 
receiving ARV’s [8]. The highest provision of ARV’s for children among the priority countries are 
Namibia with 66%, Botswana with 53% and South Africa with 49% [8]. The lowest provision of 
ARV’s to children in the 21 Priority countries are Chad 0%, Cameroon 11 % and Nigeria 12% [8].  
The reasons for low ARV provision to children are the availability of children friendly ARV’s, low 
a rate of pediatric HIV case finding , poor linkage to care and treatment, and knowledge of ARV’s 
by heath care giver  [8]. Similar pattern are seen for recommended cotrimoxazole provision to 
HIV exposed infants; only 8 countries provided cotrimoxazole for 50% of HIV exposed infants [8].  
In an Ethiopian study predictors for HIV infected infant mortality was not receiving 
cotrimoxazole at baseline, low hemoglobin, absolute CD4 count, and delayed initiation of ART 
[53]. These studies indicate that there are challenges for identifying infants, and enrolling them 
in an ART program and dispensing cotrimoxazole in a timely manner. 
Another way of reducing infection in infants is by preventing of   infection among women of 
childbearing age. The high incidence of HIV among 15-24 years old women in SSA Africa are 
attributed to gender inequality in the form of intimate partner violence , coerced sex among 
adolescent girls, age of sexual debut, relationship with older men partners and economic 
inequity [54-57]. Between 2009 and 2014 at total of 3.8 million women in the child bearing age 
group acquired HIV in the 21 priority countries [8]. The decline of new infection in women in 
reproductive age was only 15% between 2000 and 2009 (8). PMTCT programs need to engage 
male partners, but mainly biomedical and behavioral interventions have to be designed 
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specifically to this group of young women to target this hidden epidemic within the generalized 
epidemic [58, 59]. 
The Global Plan also recommends reducing MTCT to 5% by providing 90% of pregnant women in 
need of ARV for their own health. Presently, Option B+ is now being implemented since 2013 in 
most the 21 priority countries (except Cote d’Ivoire, Ghana and Nigeria) [8].  Option B+ is a fixed 
dose of ART TDF+ 3TC + EFV which is offered to HIV positive mothers for life long and it is not 
dependent on CD4 count or WHO stage [37].  The impact of adherence to ART is apparent when 
looking at the final HIV transmission rate after the end of breastfeeding period [8].  Prior to the 
launch of the Global Plan transmission rates at 6 weeks and at the end of breastfeeding  
altogether in 2009 were 28%, after the launch of the Global Plan MTCT was halved to 14% 
except for Chad and DRC which have a MTCT transmission rate of 34% and 31% [8]. Studies that 
have looked at Option B+ and adherence indicate the main reasons for not adhering were side 
effects (which included dizziness, nausea, nightmares, hallucinations), and concerns over 
partner’s acceptance of treatment, feeling healthy (not needing ART), economic concerns and 
food security [60-62] 
Significant predictors for adherence to Option B+ were adequate time and support for women 
to make decision, consistent pre-ART counseling , early support for patients experiencing side 
effects, and effort to bring women who stop ART treatment back through mother support 
groups and adherence clubs [60,61]. In the 21 priority countries 17 countries have transitioned 
to lifelong treatment Option  B+  and ARV coverage has increased  from 37% in 2009 to 77% in 
2014 [8]. In seven countries Botswana, Mozambique, Namibia, South Africa, Swaziland and 
Uganda and Tanzania the coverage for ARV for pregnant women living with HIV has increased to 
90% [8]. 
1.5 Ethiopia and HIV Response 
1.5.1 Epidemiology:  
Ethiopia is the second-largest country in Africa, which has an estimated population of nearly 
94,101,000 [63] and a growth rate of 2.6 % [64] per year. Ethiopia is a predominantly rural and 
young society, with 83.9 % percent living in the rural and 19% living in urban areas. The 
proportion of the population under age 15 is 45 %, with only 3.2 percent is above age 65 [64]. 
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Ethiopia’s Gross National income (GNI) is 1350 USD and is classified as a Low income country by 
the World Bank [63].   Ethiopia is divided into 9 regions Afar, Amhara, Benishangul-Gumuz, 
Gambella, Harari, Oromia, Somali, Southern Nation Nationalities and People Region (SNNP), 
Tigray and two City Administration’s Addis Ababa, and Dire Dawa. 
Education is a key factor in health outcomes and has a strong effect on reproductive health, 
fertility, infant and child mortality and morbidity. In Ethiopia, overall 51% women and 30% of 
men have no formal education, in the age group 15-49, 38% of women and 67% men are literate 
(DHS 2011) [64]. The total fertility rate is 4.8 children per household, women in urban areas 
have 2.6 children as compared with 5.5 children in rural areas [64].  
According to Ethiopia MDG Report in 1990 maternal mortality was 871/ 100,000, infant 
mortality was 123/1000, less than five mortality was 166.2/1000 and neonatal deaths were 
54/1000 [65]. Due to this major health system revitalization Ethiopia has made significant 
progress on the MDG Goal 4 in 2013, infant mortality rates have declined to 88/1000 births , 
under 5 mortality rates  have declined  to 60/1000 live births [65]. However the observed 
progress in reducing infant under 5 years mortality is not uniform between urban/ rural and 
geographic location [65]. 
Neonatal death have also declined to 37/1000 live births in 2011 but the reduction is minimal 
and still contributes significantly to childhood deaths [64, 67]. Ethiopia has increased primary 
health coverage to 94% by increasing the number of health posts, health centers and the 
number of hospitals [65].  Ethiopia has also increased full immunization coverage to 82.9% but 
only Addis Ababa and SNNP showed high immunization coverage while the other regions had 
lower immunization performance than the national coverage [65]. 
Of all the MDG Goals reduction of maternal mortality the MDG Goal 4 was the slowest from 
1400/100,000 in 1990, to 420 in 2013, because of delayed utilization of skilled care, limited 
availability of emergency obstetric and newborn care, and low post-partum visit [65, 68]  
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1.5.2 Health System and Health Policy: 
The health sector has introduced a three-tier health care delivery system [69, 70]. Level 1 
comprises of a primary hospital (to cover 60,000-100,000 people), health centers (1/15,000-
25,000 population) and their satellite Health Posts (1/3,000-5,000 population) connected to 
each other by a referral system. The health center and health posts form a Primary Health Care 
Unit (PHCU) Level 2 is made of General Hospital covering a population of 1-1.5 million people; 
and Level 3 are Specialized Hospital covering a population of 3.5-5 million people [69, 70]. 
With the decentralized government structure, decision making for public service delivery is 
under the authority of the regions and districts. The Woreda (District) Health Offices manage 
and coordinate the operation of the district health system under their jurisdiction. The Woreda 
Health Offices use the Health Sector Development Programs (HSDP) as the basis for developing 
the annual plan at all level [69, 70]. 
Following the change of government in 1991, the new Government of Ethiopia first national 
health policy, which was followed by the formulation of consecutive phases of comprehensive 
Health Sector Development Programs (HSDPs)  forming a twenty year strategic roadmap for the 
health sector. Health Sector Development Programs (HSDPs) are designed to take in account 
national health policy, strategies and prevailing national health problems and emerging health 
problems in the country [69, 70]. 
HDSP I: 1997/98- 2002  
HSDP II: 2003-2005  
HSDP III: 2005/6 -2009/2010 
HSDP IV:  2010/11 – 2014/15 
The current HSDP IV 2010/11 to 2014/15 main strategic directions are: strengthen health 
extension program (HEP), improving quality of health care, scaling up civil service reform, 
focused attention on maternal health, TB, and PMTCT program’s. Other HSDP IV focus areas are 
health resource development, health infrastructure, addition support to regions that lag on 
targets, climate change and disparities on health and gender [71]. 
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1.5.3 HIV Epidemic  
The HIV/ AIDS epidemic in Ethiopia, similar to most Sub Sahara African countries, began in the 
late 1970 or early 1980’s [72].  The first HIV positive patient was reported by Lester et al in 1986 
among hospitalized patients at a hospital in Black Lion Hospital, Addis Ababa [73]. HIV/AIDS was 
also detected among 5,565 military recruits showing a prevalence of 0.07 % [74]. The epidemic 
was mainly concentrated in urban areas among most at risk population (MARP) such as 
commercial sex workers (17%) who resided along the main trading routes, truck drivers (13%) 
[75-77]. A 1990 papers indicated that HIV prevalence was increasing substantially in commercial 
sex workers in Addis Ababa [76-77]. In 1985 the Department of AIDS that consisted of the 
National Task Force on the Prevention and Control of HIV and AIDS and the National AIDS 
Control Program was established [78]. This facilitated the drafting of the first AIDS Policy, the 
establishment of a surveillance system, and initiation of HIV/ AIDS education for the most at risk 
population [78]. 
In 1991 the Dergue government was overthrown and Ethiopian People's Revolutionary 
Democratic Front (EPRDF) took office. The 30 year civil war that culminated with an EPDRF 
victory exacted heavy tolls on the whole country [79].  A large number of hospitals in the 
northern part of the country where the war was taking place had been destroyed or was not 
functioning. (86) In 1990 coverage of health facilities was estimated at 45%, only 16% of  
mothers  attended ANC, 5% of deliveries were assisted by health personnel, EPI coverage was 
26% for mothers and 13% for children, CPR was 4%, and only 19% of people had access to safe 
water [79]. 
In 1999 the new government issued a 5-year Multi Sectoral HIV/AIDS Strategic Plan for 2000-
2004. The objective of the strategic plan is to reduce HIV transmission and HIV/AIDS morbidity 
and mortality [80].  HIV prevention mainly centered on behavior change on safer sex messages 
using condoms, and radio programs directed to the youth, community based methods such as 
drama, art, and peer education [81]. Voluntary counseling and Testing (VCT) services were 
scarce between 1995-2000 and only 1.0% of people in rural areas and 9.3%  in towns reported 
on being tested but 64% of rural and 69.4% of urban respondents wanted to be tested indicating 
high levels of unmet demand [81]. 
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The mid 1980’s to 2000 can be characterized as very limited funding, implementation of HIV 
programs was low, HIV/AIDS policy was just issued and there was no guidelines or training 
materials for HIV,  tuberculosis (TB), sexually transmitted disease (STI),  blood safety, VCT, 
PMTCT, ART, opportunistic infections (OI surveillance), and  monitoring and evaluation (M&E) 
[78].  
In 2001 MOH issued guidelines for ARV treatment, VCT, a handbook for HIV/AIDS home care and 
a policy for ARV supply and use [82-85]. The ART program was launched in July 2003 for only 
those who can pay and the cost was between 30-90 USD per month depending on the ART 
selected [81].  Diagnostic lab test for CD4 was also available for only those who can afford to pay 
36- 80 USD [81]. The ARV was dispensed only from the Ethiopian Red Cross Pharmacy and a 
Municipality Pharmacy. At the end of 2004, 9,700 people were on treatment nationally [81]. 
 In 2003, the adult HIV incidence in the urban area was 1.82% while for the rural it was 0.46% 
[86]. The estimated national adult prevalence was 4.4% of which 12.6% was urban and 2.6% was 
rural. The cumulative number of people living with virus was 1.5 million (3.8% males and 5% 
female, 12.6% urban, 2.6% rural), 96,000 were children >15 years of age. The estimated new HIV 
case adult population was 98,000 (46% male and 54% female), 245,000 PLWHA were in need of 
ART, 90,000 adults and 25,000 children died from HIV/AIDS related causes.  At the end of 2003 
there was an estimated 539,000 AIDS orphans [86]   
In January 2005 the government launched a free ART program and by the end of July 2006, 
45,595 patients were started on ART at 132 facilities.  Of the clients starting on ART 47% were 
adult males, 48% were adult females, and 4% were children. The national adult prevalence 
decreased to 3.5% and it was estimated 1.32 million people were living with HIV AIDS, and there 
was 128,900 new infections altogether of which 30,300 were infants [87]. 
Since 2005 HIV incidence and AIDS mortality have declined according to the last Ethiopian 
Demographic Health Survey 2011 the adult HIV prevalence is 1.5% [64]. However prevalence 
varies according to age, sex, gender and regional location [64].  The HIV prevalence rates in 
woman were twice as high compared to males (1.9% versus 1%) [64]. The distribution of HIV 
prevalence also varied by age peaking earlier in female’s 30-34 age groups as compared to 35-39 
in males. [64]   The HIV epidemic is concentrated in urban areas with 4.2% prevalence as 
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compared to 0.6% prevalence in rural areas.  HIV prevalence is highest in the Gambella region, 
Addis Ababa, and Dire Dawa and it is lowest in SNNPR and Oromia have the lowest prevalence 
[64].  
Antenatal sentinel surveillance in 2011 indicates that HIV prevalence among pregnant woman 
aged between15-49 has declined both in urban and rural areas [64].  HIV prevalence in urban 
areas for women between15-49 declines from 14.3% in 2001 to 4.4% in 2012 and in the rural 
areas it declined from 4.1% in 2003 to 1.8% in 2012 [64]. 
High risk population are diverse and not well delineated  but past studies have shown female 
sex workers, seasonal mobile workers, university and high school students, uniformed services, 
prisoners, truck drivers, and sero-discordant couples may be at higher risk for HIV infection [88]. 
The main reasons for the decline of HIV in Ethiopia are: 1) rapid expansion of HIV testing and 
counselling and behavioral change programs through the Keble (the smallest administrative unit 
equivalent to a ward or neighborhood), involvement of Health Extension Workers at community 
grass root level, rapid expansion of ART coverage, high rates of male circumcision (92%), low 
rates of pre-marital sex and low rates of extramarital sex. [99] 
1.5.4 PMTCT  
PMTCT guideline was published in 2001 but facility based service delivery was initiated in 13 
pilot health centers on Feb 2004 (program launched September 2003) [89]. The Hareg 
Prevention of Mother-to-Child Transmission (PMTCT) Project was funded by the U.S. 
Government’s   and the treatment was based on WHO Guideline 2001 Data from the first 13 
sites indicate only  55% who were pretested were counselled, there were 627 pregnant women 
who tested positive, 221 women  and 161 infants who took NVP [89].   In 2005, FMOH AIDS 6th  
report  indicates that a total of 52,428 pregnant women were tested for HIV, 4,172 tested HIV 
positive, of these 2,208 (52.9%) of the pregnant women and 1341 (32%) of their infants received 
nevirapine for PMTCT [87].  Facility based PMTCT services start increasing nationally from 32 
facilities in 2004 to 129 facilities in 2005, 2012 there were 1901 facilities with PMTCT services 
[88].   
 
 
Page 25 of 76 
The first national PMTCT guidelines in Ethiopia were developed in 2001, but were only 
implemented in 2003 in limited public health facilities.  The 2001 National PMTCT Guideline was 
in line with WHO 2001 recommendation of sdNVP [91]. Due to lack of free access for ARV 
prophylaxis the implementation of the basic PMTCT package remained a challenge until 2005 
[87]. The 2001 National PMTCT Guideline was revised in 2007 and this incorporated WHO 
PMTCT 2004 and 2006 revisions which were HIV counseling and testing from the opt-in to the 
opt-out policy, initiation of first line regime AZT+ 3TC+ NVP for mothers with CD4 <200 cells/µL, 
and women who were not eligible for ARV’s should initiate AZT starting at 28 week [92]. The 
2007 National PMTCT guideline was revised again in 2011 in line with the WHO 
recommendations 2010 of Option A [93]. The two key revisions from WHO PMTCT 2010 that 
were incorporated into the new 2011 National PMTCT Guidelines are the increase of CD4 count 
from <200 to <350 as cut off point for ART initiation and ARV prophylaxis for women who are 
not in need of ART for their own health can start ARV as early as 14 weeks of gestation [93].   
Simultaneously, in 2011 Federal Ministry of Health (FMOH) came up with the new Accelerated 
PMTCT strategy and coordination plan [94]. The FMOH set ambitious PMTCT national targets for 
2015 in the Fourth Health Sector Development Program, to provide ANC service to 90% of 
pregnant women, to ensure all women are attended at delivery of which at least 62% should be 
cared for by skilled health attendants and 38% health access workers and lastly to provide ARV 
prophylaxis to 80% of HIV positive pregnant women [94].   In 2013 the National PMTCT 
Guideline was revised to the Option B+  after  Ethiopia signed on to The Global Plan towards the 
Elimination Of new HIV infections among Children by 2015 and keeping their mother alive  2011 
[95]. In 2013, FMOH  Revised the  PMTCT guideline to  WHO 2013 Option B+  regimen and also 
developed MTCT Elimination Plan (eMTCT)  with the goal to provide Option B+ to 95% of HIV 
positive pregnant women, reduce new infections among reproductive women by 50%,and 
reduce unmet need by of family planning by 10% and reduce MTCT to less than 5%  [96,97]. 
1.5.5 Antenatal care as entry point to PMTCT 
Antenatal care during pregnancy is the first intervention in order to maximize the chances of 
preventing mother-to-child transmission.  Nigatu et al. have analyzed national PMTCT data from 
2004 - 2009 and the antenatal care service coverage for at least one visit during pregnancy 
increased from 50% in 2006 to 71% in 2010 [98]. The same study also looked at PMTCT services 
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at ANC clinics between 2006 and 2010, reporting an increase from 171 PMTCT service sites in 
2006 to 1352 sites in 2010. Paradoxically, the expansion of PMTCT sites didn’t coincide with an 
increase in mothers receiving PMTCT services at ANC clinics. According to the 2006-2010 
national PMTCT data report 1.3 million pregnant mothers that attended ANC sites were not 
provided PMTCT service [98]. 
In 2013 the total number of health facilities that provided PMTCT services has increased to 
2,150 which mean 64.4% of public hospitals and health centers provide PMTCT services.  Among 
the 2.3 million pregnancies in 2013 80% of the expectant mothers attended ANC [99]. 
Counseling, HIV testing at antenatal sites with PMTCT services generally faces challenges for 
obvious reasons of client’s fear of result, concerns of confidentiality, fear of disclosing results to 
partners, and fear of discrimination [100].  Nevertheless, acceptance of HIV testing has 
dramatically increased Ethiopia between 2006- 2010, the number of women that have accepted 
counseling and testing rose from 57% in 2006 to 92% in 2010 [98].  The increase is partially due 
to the fact HIV Testing and Counseling guideline changed in 2008 from the “opt –in’ approach to 
the “opt out” approach [101] 
 Despite the significant progress, 300,000 mothers who received counseling service did not 
receive HIV testing at antenatal clinics from 2006 to 2010. According to Nigatu et al. in 2010, an 
average of 326 women present for ANC every work day missed HIV counseling services.  
However the number the of HIV positive women that have not been counseled at ANC sites has 
decreased from 230,000 in 2006 to 85,210 in 2010 [98]. 
National PMTCT data analysis in Addis Ababa between 2004- 2009 indicates that 663,603 
pregnant women attended ANC and 24.6% was new attendees, overall 135, 196 women and 
6,664 partners received HIV counseling and 6.2% (8,467) were HIV positive [101]. 
The Multi-Sectoral HIV response report for 2012/2013 indicates that there still remain missed 
opportunities for HIV Counseling and Testing. In 2013 there were 2.9 million expected 
pregnancies and 80% pregnant mothers attended ANC but only 70% of them were counseled 
and tested [99].   
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1.5.6 ARVs as essential component of PMTCT in Ethiopia 
Free access to ARV prophylaxis became available in 2005 in Ethiopia  [87] National ARV coverage 
for mothers and infants is one of the major challenges that Ethiopian is still PMTCT program is 
facing in 2015 (8) .   
A five year national level PMTCT data analysis (2006-2010) by Nigatu et al. revealed that 56% of 
women received ARV’s, while 44% of pregnant HIV positive mothers didn’t receive ARV 
prophylaxis [98].  Similar trend is observed in the analysis of monthly PMTCT reports from Addis 
Ababa between 2004 and 2009, ARV prophylaxis uptake was 42.4% for mothers and 31.08% for 
infants in cohort of 8,467 HIV positive pregnant women [101]. 
In a 2010 cohort study in Addis Ababa that looked at 282 HIV positive pregnant women, 232 
initiated medications during pregnancy, 154 initiated ZDV prophylaxes and 78 lifelong ART. 
Among  the 232 women that initiated medication during pregnancy, only 171 ingested 
medication during labor, and this was strongly associated to giving birth at health facility (OR 
13.64, 95% CI 4.64—40.12) [102].  
A PEPFAR data analysis from 2013 indicated that 17,742 women were found to be HIV positive 
and only 75% of these identified received ARV and even fewer of their infants received ARV 
prophylaxis [99]. The Global Plan 2015 also showed that in 2013 in Ethiopia there was only 16% 
ARV Coverage for children and in 2014 the coverage increased to only 22% [8]. In spite of 
challenges faced at every step of the PMTCT cascade, the number of HIV positive pregnant 
women who were identified, took ARV has increased by several folds between 2006- 2013 [99].  
1.5.7 Early Infant Diagnosis and Mother to Child Transmission rate 
WHO recommends that infants exposed to HIV should be tested between 4 and6 weeks and if 
infected should start treatment immediately [45].  Infants infected in utero, during labor or 
deliveries have a poor prognosis compared to those infected during breastfeeding, they require 
urgent ARV to prevent early mortality [103].   
The PMTCT national data analysis from 2006-2010 by Nigatu et al. showed that 56% of HIV 
exposed infants did not receive ARV prophylaxis [98].  Similar trend were observed by a 2011 
retrospective study done by Mulatu et al. which analyzed data from 2008-2009 in Zeweditu 
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Memorial and Yekatit Hospital from 118 HIV exposed infants [49]. The study showed the ARV 
uptake at birth was 91%, but eventually 31% of the infants were lost to follow up and their 
cotrimoxazole treatment interrupted [49].  
In the cohort study by Mirkuzie in 2009 out of the 221 live births from HIV positive mothers, 115 
infants received their first EID diagnosis but only 71 received documented results. The   mother 
to child transmission rate was approximately between 8.2 % and 9.5% [102]. The main reasons 
for not having documented EID  test results were : 1) results were not collected from the central 
laboratory, 2) misplacing of results at the facilities, 3) DBS not collected from infants due to lack 
of training [102].   
Follow up on HIV testing on infants also faced challenges as reported by another retrospective 
study by Mirkuzie et al [101]. From 2004-2009 only 896 (10.6%) infants completed the follow up 
HIV testing, of which 106 infants were found to be positive. The  mother to child transmission 
rate calculated for the cohort of infants  in 2006  that were on sdNVP regimen tested at ≥ 18 
month was 14.3%, and  the MTCT rate for infants in  2007  was 14.9% ,and in 2009 the MTCT  
rate was 8.2% , this decline may be due to guideline change in 2008  to  the more  efficacious 
ZDV regimen [101]  
The major determinants of mother to child transmission in Ethiopia have been discussed in two 
retrospective follow up  studies that were done in  Ethiopia at Gondar University Referral 
Hospital from 2005-2011 and Dil Chora Referral Hospital from  2005-2013. (104,105) Both 
retrospective studies had similar findings on the major predictors to mother to child 
transmission, which were delayed infant linkage to care, rural dwelling, delivery at home, mixed 
feeding, infant not receiving ARV prophylaxis at birth, mother infant pair not on ARV [104,105]. 
In Gondar University Hospital the MTCT rate was 10% and at Dil Chora Hospital it was 15.7% 
[104,105]. 
The Global Plan Progress report for 2015 for Ethiopia indicates the number of new infections 
among children between 0-14 years old in 2013 and 2014 were 7000 and 4800, the MTCT rate at 
6 weeks was  8% and 6%, and at the end of the  breastfeeding period increased to 30% and 26%, 
respectively [8].  
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Nevertheless, even if the infant is successfully tested and linked to the health system, 
sustainability of access to treatment and care of children remains a challenge. The ARV coverage 
of children in Africa according to the 2015 Global Plan update on HIV in the WHO Region is 
estimated at 31% and in 2011 it was 26% which shows that there hasn’t been any progress [8].  
A qualitative study by Baidgilin et al. on the barriers to ARV adherence among HIV infected 
pediatric patients that was conducted in 6 selected hospitals in Addis Abeba indicated 1) heavy 
pill burden, 2) stigma and discrimination, 3) cost and access to transportation, 4) economic 
problems at the house, 5) lack of nutritional support, 6) lack of medication understanding – as 
barriers for ARV adherence [106]. 
In 2015 out of the 22,000 children infected through mother to child transmission 190,000 
children resided in Africa, although vertical HIV transmission could easily be prevented [1].  In 
high income countries, peri-natal transmission is less than 1% due to caesarian sections and 
effective uptake of antiretroviral therapy (ARV) by HIV positive pregnant women [25].  In low 
and middle income countries PMTCT coverage is low and in consequence transmission rates 
remain high [25, 44]. 
 
1.6 Summary 
Although the advance in PMTCT regimen suitable for  low income regions such as Sub-Saharan 
Africa implementation of these findings have been slow compared with the rapid 
implementation of these findings in the mid 1990’s  in high income countries and the decline of 
MTCT presently  to 1-2%.  This is despite major initiatives such as GAFTM, PEPFAR, Bill Melinda 
Gates Foundation and Clinton Foundation who have made treatment access a reality to millions 
of people in SSA. Even though there are many factors for this slow progress, the main factor is 
political will and weak health infrastructure.   A testimonial for political will is Cuba which 
became the first country to formally validate the elimination of MTCT [8]. Botswana and 
Thailand are also good examples of how the political will of the government has been able to 
reduce MTCT below 5% [25]. It is important for PMTCT programs in low income countries adopt 
factors that made PMTCT a success from other countries but also address factors for failures 
within their own programs in order to achieve better result. 
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1.6.1 Problem statement: 
Ethiopia PMTCT program is relatively young, approximately 10 years (2005-2015), since the 
complete basic PMTCT package has been rolled out nationally; there has been impressive 
progress in this short time frame.  This study looked at PMTCT intervention outcomes such as 
ART regimens, obstetric practices, breastfeeding, and linkages of HIV positive infants to HIV care 
and treatment at 7 health centers in Addis Ababa. Even though the study results cannot be 
strictly generalized to all the health centers in urban Ethiopia, the findings of this study may 
assist to improve PMTCT care services in connection to the new 2013 Nation MTCT Elimination 
Plan (eMTCT)  with the goal to provide Option B+ to 95% of HIV positive pregnant women, 
reduce new infections among reproductive women by 50%,and reduce unmet need by of family 
planning by 10% and reduce MTCT to less than 5%  [96].  
 
1.7 Objectives 
The general objective of the study was to assess PMTCT uptake level and the subsequent linkage 
of infants to HIV care and treatment services.  
The specific objectives were:  
1. To assess adherence to ARV treatment by HIV positive pregnant mother before and 
after delivery  
2. To identify factors associated with poor ARV adherence in HIV positive pregnant mother 
3. To assess the proportion of HIV exposed infants linked to services 
4. To identify factors associated with linkage to HIV care services among HIV exposed 
infants 
Peri- and post-partum PMTCT practices were not influenced by the study and following 
Ethiopian Guidelines. The study describes PMTCT procedures and evaluated outcome on an 
observational basis. 
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2. Methods 
2.1 Study Sites 
The study was conducted in Addis Ababa with a population of 3 million. The city is divided into 
10 sub-cities. In 2013, 54 health facilities provided PMTCT service utilization in Addis Ababa, 
presently in 2015 73 health facilities provide PMTCT and 24 sites are under construction.  The 
study took place in seven Health Center’s (HC): Gulele HC, Kolfe HC, Sheromeda HC, Sarris HC, 
Bole HC, Mesholekya HC and Sarris HC. The seven health centers are located in sub cities 
bearing their names except for Sarris Heath Center HC is located in in Nifas Silk Lafto Subcity,  
Sheromeda is located in Gulele Subcity, and Mesholekya HC is located in Kirkos Subcity (Figure 
1).  The health center is a primary health care unit with in-patient and out-patient services 
including surgery, and laboratory services. A health center with PMTCT facilities  can provide 
ARV prophylaxis, manage STI’s, diagnose and treat UTI, anemia, TB , malaria and intestinal 
parasites, follow up on HIV exposed infants, attend to delivery, immunize infants, and counsel 
clients on HIV related matters. On average in each health center there are 4 nurses in the ANC 
department and 10 midwives in the delivery department and 3 nurses in Expanded Program on 
Immunization (EPI) department and 5 nurses working in the ART Department. 
Figure 1.  Addis Ababa is divided into 10 sub cities; Gulele, Yeka, Bole, Akaki- Kality, Nefas- Silk 
Lafto , Kolfe-Keranio, Addis Ketema, Lideta, Kirkos, Arada. 
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2.2 Study Design:  
The Study is a prospective, observational cohort study of HIV positive mothers and their 
pregnancy through the time of delivery and until six weeks after delivery. 
2.3 Study Populations: 
HIV positive pregnant women that attended antenatal care service were recruited from seven 
health centers in Addis Ababa. The outcome analysis included recruited mothers and their 
infants. 
2.4 Duration of the study 
The recruitment period October 2012 and July 2015 and the total study period took 
approximately three years. 
2.5 Eligibility criteria 
2.5.1 Inclusion criteria  
1. HIV positive pregnant mothers  
2. Age 18 years or above 
3. Willingness to provide information and data collected on their HIV status, PMTCT 
procedures, health status, personal characteristics as well as health information of their 
infant(s) 
4. Voluntary written informed consent 
2.5.2 Exclusion Criteria 
1. Mental or physical incapacity (including ongoing labor) leading to inability to provide 
informed consent 
2.6 Schedule of Events 
The following flowchart summarizes study procedures including: 
1. Recruitment of HIV positive pregnant woman at the antenatal care clinic 
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2. Perinatal assessments including pre- intra- and post-partum procedures 
3. Early infant diagnostic procedures 6 weeks after delivery 
All procedures are based on Ethiopian National PMTCT Guideline. Standard laboratory 
measurements will be based on local laboratory practice 
 
Table 3:  Schedule of Event 
 
Procedures Ante-
partum 
Delivery 
Post-partum 
Day-6 Week-6 
Informed consent x    
Tracing Information x    
Baseline & Socio-demographic  Information x    
HIV History x  x x 
CD4-count x    
ARV Treatment History x x x x 
Gestational Age, Onset of Labor, Premature 
Rupture of Membrane, Perinatal ARV 
x x   
Type, Duration and Complications of Delivery  x   
Infant Outcome (number of infants, APGAR, 
height, weight) 
 x   
Counseling Breastfeeding and Infant’s ARV 
Prophylaxis 
 x x x 
Adherence of ARV Infant Prophylaxis   x   
Adherence of Mother ARV Regimen   x x 
DBS-EID (infant)   x x 
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2.7 Recruitment and inclusion procedures 
Women presenting for antenatal care at participating health care facilities at the health centers 
were counseled and offered HIV antibody testing by a PMTCT nurse, as per the standard of care 
provided at that site. Women were provided introductory information about the study if either 
they were discovered to be HIV infected and agreed to receive their test results, or they already 
knew there HIV status from previous HIV testing. They enrolled as early as their first antenatal 
visit after their HIV infection is confirmed. At that point, the study was described to them as part 
of a screening and consent process. The following primary eligibility criteria were used to 
determine which women may be invited into the study: 
 Age  18 years. 
 Evidence of HIV infection, as documented by 2 positive EIA's; or 1 positive EIA; or 2 
separate concurrent rapid tests. These are the WHO acceptable criteria for 
diagnosing HIV–1 infection in adults. 
After the screening and consenting process, the study case report form’s for Antepartum Visit -1 
and a  Compliance Questionnaire for  PMTCT Antiretroviral Treatment Adherence was used to 
document the client’s information. The Antepartum Case Report Form asked questions on 
demographics, HIV History, ARV history, obstetric and previous pregnancy, current pregnancy 
and lab diagnostics. The compliance questionnaire mainly concentrated on adherence to the 
ARV’s on the last 4 days, last month.   
2.8 Informed consent procedures 
Patients underwent informed consent procedure prior to any study related activity. A consent 
form template in Amharic was provided to the client.  The informed consent procedure was 
conducted by a study nurse. After the study was fully explained and answers were responded, 
written informed consent were obtained from the patient. In the case of illiterate study 
participant a thumb print was provided by the patient. The signed consent form was kept in in a 
locked cabinet throughout the study period.  After the informed consent has been signed the 
first clinical Antepartum case report form was used to collect data from the client.  
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2.9 Adherence Questionnaires  
Starting from the first visit antenatal care, delivery, at day 6 and week 6 the maternal ART status 
was asked and maternal adherence to antiretroviral treatment was assessed using a self-
administered questionnaire. The 5-items questionnaire included (i) a 4-day recall asking for 
numbers of skipped doses (never, 1 , 2, 3 or 4 skipped doses), (ii) a 1-month recall of voluntary 
treatment interruptions (never, less than one weeks, 1 to 2 weeks, more than 2 weeks), (iii) an 
ordinal question of skipped doses and (iv) shifted doses more than two hours over the last 
month (never, rarely, often), and (v) a question about following prescription over the past 
month (totally followed, generally  followed, often modified, almost never  followed 
prescription, or interrupted treatment). Infant’s assessment included up-take of Nevirapine 
(NVP) prophylaxis and adherence, using an adapted 5-items questionnaire related to difficulties 
in administering infant prophylaxis administered at day 6 and week 6 post-partum. 
2.10 Data and sample collection during delivery 
As a standard practice mothers delivered in the health centers where they received antenatal 
care. However, if the mother is transferred to another health facility or delivered at home, the 
data was collected when she came for her 6th day and 6th week postpartum visit. In the event 
that the mother cannot be found, tracing information was used by mother support group to re-
establish contact. Intra-partum case report form and Adherence questionnaire was used to 
collect information on delivery and ARV taken during delivery. The Intrapartum Case Report 
form collected information on the type of delivery, newborn health, and ARV history. 
2.11 Data and sample collection during the Postpartum 6 days and 6 weeks visit 
According to the Guideline for Prevention of Mother to Child Transmission of HIV in Ethiopia 
2011 post-partum care is required at 6 hours, 6 days and 6 weeks (6-6-6). Mother’s came in for 
the first infant penta-valent vaccine and to have blood collected from the infant for EID at 6 
weeks. All PMTCT Health centers have trained nurses that can collect blood using filter paper 
from the heels of infants. At 6 weeks mother support group coordinator according to follow-up 
dates called and reminded study clients of the EID collection dates. Data collection forms for 
Postpartum 6 day, 6 week, Infant Linkage and Adherence Questionnaire were filled out on 6 day 
and 6 week accordingly on the respective dates. Postpartum 6 day and 6 week questionnaires 
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collected data post- partum on mother health, child health and ARV history. Infant Linkage 
Questionnaire main focus was DBS Collection dates, DBS result received date, DBS result and 
infant linkage to care. 
2.12 Laboratory procedures  
Laboratory tests were performed at the respective health centers according to the national 
standard of care for HIV-positive pregnant mothers. All health centers are equipped with 
hematology, chemistry and CD4 analyzer. The standard of care for lab exams for HIV-a positive 
mother is a urine analysis test; hematology, liver function test and CD4 count. The lab results 
the study used was only for CD4 counts. 
2.13 Statistical and Sample Consideration 
An estimate of the sample size was computed based on a population proportion of 72% for 
adherence rate [107, 108]. A sample size of 310 pregnant women is found to be sufficient to 
achieve a confidence interval of 95% with a marginal error of 5%. The following formula was 
used to calculate the desired sample size. 
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In order to compensate for LFUP, 15% compensation was considered which increased our 
sample size to 357. Since we assumed that some respondents might not respond to all the 
questions, hence 5% non-response compensation was considered. The total amount of 
participants needed for the study after considering LFUP and non-response compensation was 
375. 
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2.14 Sampling 
Based on the recommendation of the city health bureaus sample health centers were selected 
purposively on the basis of high client flow. The quarterly reported number of HIV positive 
pregnant women attending health centers were considered in identifying the following study 
sites: Gulele HC (51), Kolfe HC (96), Kirkos HC (59), Sarris HC (111), Bole HC (49) , Mesholekya HC 
(70)  and Sheromeda HC (58).   
2.15 Data collection, management and analysis 
Data was collected on case report forms (CRF), transcribed from questionnaires, lab reports, 
medical charts and interviews with patients. The questionnaires were pre-tested for reliability 
and validity by administering the questionnaire to a small number of people who resemble the 
population of interest. The information provided by the respondents was then be analyzed for 
the clarity, question wording, or response categories. Data collection was accomplished by 21 
trained PMTCT nurses in seven health centers, that worked in either antenatal or delivery 
section.  The study staff was trained for 1 full day on the purpose of the study, confidentiality, 
ethical consideration and data collection prior to the study start date 
Data collection and analysis was done in close collaboration with key stakeholders including the 
health center PMTCT staff, Addis Ababa Regional Health Bureau and Addis Continental, Institute 
of Public Health. Only de-identified data was used in this analysis.  
Clinical and laboratory data were recorded in study specific case report forms and entered into a 
study tailored database which was programmed in Epi Info (CDC Atlanta, Version 3.5.3). Data 
was double checked for validity by the researcher on several occasions during the study period. 
The data entry software included applicable edit checks such as valid values, range checks, skip 
patterns and inconsistency checking.  
2.16 Statistical methodology 
Descriptive statistics were reported for maternal baseline characteristics, HIV and ART 
associated information, infant outcome, infant prophylactic treatment and EID information. 
Treatment adherence was graded as good if all adherence questioners indicated optimal 
compliances (no interruption, never shifted or skipped doses, totally followed prescription); 
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moderate if doses were once or rarely skipped or shifted, or prescription were generally 
followed; poor if doses were more than once or often skipped or shifted, or prescription were 
often modified or worse. Adherence grades were assessed for mothers and infant for each time 
point (delivery, day 6 and week 6). Combined post-delivery or overall adherence was 
summarized, and discrepant adherence grades by different time-points were combined based 
on the worst case for adjacent grades (poor + moderate = poor) or using the middle value (poor 
+ good = medium). Comparison of treatment adherence before and after delivery was 
performed using the McNemar’s exact test.  Study site adjusted Poisson regression with robust 
variance estimates was used to analyze socio-demographic and HIV related risk factors 
associated with poor antiretroviral treatment adherence. For all statistical tests an alpha level of 
<0.05 was used to define significance.  All statistical analyses were performed using Stata 
statistics software (version 14, StataCorp, College Station, TX, USA). 
 
2.17 Ethical Considerations  
2.17.1 Involvement of Ethics Committees 
The protocol and the informed consent document to be used in this study was submitted to the 
Addis Continental Institute of Public Health and the Addis Ababa Regional Health Bureau ethics 
committee’s written documentation of approval of both the protocol and the informed consent 
was  provided before starting the study. 
The site principal investigator ensured that the purpose of the study is explained to the patient 
and that written consent is obtained prior to participation in the study. The patient and the 
study nurse signed the consent prior to entry into the study. The investigator retained a copy of 
the signed consent forms. 
The investigator promptly reported to the Ethics Committee/IRB of all changes in the research 
activity and all unanticipated problems involving risks to human subjects or others, and did not 
make changes in the research without Ethics Committee/IRB approval, except where necessary 
to eliminate apparent immediate hazards to human subjects. 
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2.17.2 Risks and benefits 
This was an observational study following procedures recommended by the Guidelines for 
Prevention of Mother to Child Transmission of HIV in Ethiopia, issued by the Federal Ministry of 
Health in 2011. Therefore, the risks of participating in this study did not exceed the risks induced 
by the routine health services. Additional risk by the study was minimal and is as follows: the 
primary risks to study participants are potential social harm from stigma. All study sites have 
had ongoing ART for at least one year to date. Stigma and potential harm from society were real 
causes of concerns in prior years of HIV care but presently due to behavioral change educations 
on HIV this problem has been reduced. Breach of confidentiality is greatest during enrollment 
and the interviewing stages of the study, steps were taken to mitigate that risk. In addition to 
procedures that were put in place to assure participant confidentiality, participants were not 
identified in any reports on this study and no patient identifying information were extracted 
from clinical records. Any copies of case report forms and data forms bearing any identifiers 
were kept in locked secured areas.  
2.18 Participant identification 
For the study each participant will received a unique study number which was the only identifier 
on the case report forms and within the database. A study Screening Log was maintained in 
which hospital identifier were linked to the study participant ID. The Screening Log was only 
accessible by assigned study staff and kept within the study regulatory binders. 
2.19 Confidentiality and Privacy 
Data abstraction forms and laboratory specimens were identified by coded number only, in 
order to maintain subject confidentiality. All records were kept locked. All computer entry and 
networking programs were done with coded numbers only.  
2.20 Insurance 
As a minimal risk study participant insurance was not requested.  
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2.21 Data Dissemination 
The study data is for a PhD thesis leading into a written report submitted to the Center of 
International Health at the University of Munich (LMU). After completion of the study, the data 
will be considered for reporting at local health forum, national and international scientific 
conferences or for publication in a scientific journal. The study PI  will be responsible for these 
activities and will collaborate with the investigators and collaborators of the study to determine 
how the manuscript is written and edited, the number and order of authors, the journal to 
which it will be submitted and other related issues. Proposals for scientific presentations and 
publications need to be communicated with the study PI who will organize involvement and 
harmonization with the scientific study collaborators. 
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3. Results 
3.1 Study Flow 
Between October 2012 and July 2015 494 HIV infected pregnant women were enrolled into the 
study. Following study enrolment 17 (3.4%) women decided to continue PMTCT and obstetric 
services outside the study sites, 7 (1.4%) were actively transferred to higher level health facilities 
due to pregnancy of obstetric problems with reasons and infant outcome, and  7 (1.4%) did not 
continue with study procedures due to abortion or fetal death before the date of delivery  
(Figure 1).  In addition, 2 women actively decided to not continue with PMTCT procedures and 
19 women were lost to follow-up for unknown reasons before delivery. Of the remaining 442 
women who were followed up during delivery 19 mother/infant pairs did no continue study 
procedures until week 6 post-partum either due continuation of post-natal services at other 
health facilities (N=5), still birth (N=6) or early infant death (N=3), maternal death (N=1), or 
rejection to continue with post-natal PMTCT procedures (N=3). Defining missed retention to 
PMTCT services for those women who at any time during the study period actively rejected 
PMTCT procedures (N=5) or were lost to follow-up without receiving tracing information (N=19), 
in total 24 (4.9%) women met these criteria throughout the entire study period. Reason for early 
termination of PMTCT services could not be determined for all of those women, frequent 
reasons which could be assessed were finical constrains, HIV stigma, distance of health center 
from home location, and rejection of ART. 
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Figure 2: Study Flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruited during ANC 
N=494 
Followed up at Delivery 
N=442 
Followed up at Day 6 
N=434 
Followed up at Week 6 
N=424 
Attended other health facility N=17 
- Stillbirth (N=2) 
- Infant not HIV infected (N=4) 
- Infant outcome unknown (N=11) 
Active transfer due to pregnancy/obstetric problem (N=7) 
- Prolonged labour and stillbirth (N=2) 
- Prolonged labour, infant outcome not known (N=1) 
- Breech presentation, infant outcome not known (N=1) 
- Premature rupture of membrane, infant outcome not known (N=1) 
- Eclampsia, infant not HIV infected (N=1) 
- Infant respiratory distress and death (N=1)  
Abortion/fetal death (N=7) 
Actively rejected PMTC procedures (N=2) 
- Infant HIV infected (N=1) 
- Infant outcome unknown (N=1) 
Lost-to-follow up, infant outcome unknown (N=19) 
Actively rejected PMTC procedures (N=2) 
- Infant HIV infected (N=1) 
- Infant outcome unknown (N=1) 
Abortion/fetal death (N=7) 
Lost-to-follow up, infant outcome unknown (N=19) 
 
Stillbirth (N=6) 
Early infant death, reason unknown (N=1) 
Rejected PMTCT procedures, infant outcome unknown (N=1) 
Rejected PMTCT procedures, infant outcome unknown (N=1) 
Completed at other health centre (N=5) 
- Infant not HIV infected (N=1) 
- Infant outcome unknown (N=4) 
Mother died, infant not infected (N=1) 
Referred mother due to previous eclampsia, infant died (N=1) 
Early infant death, pneumonia (N=1) 
Rejected further PMTCT procedures, infant outcome unknown (N=2) 
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3.2 Sociodemographic characteristics  
Woman’s study site affiliation, baseline demographic, socioeconomic, educational, occupational 
and HIV status characteristics are shown in Table 4.  In brief, the median age was 28 years, the 
majority of women were married, Orthodox Christians, had primary or secondary school 
degrees, were house wives or private employees, with a median monthly family income of 1000 
Ethiopian Birr (around 47 USD).  
Table 4: Study site affiliations and baseline demographic, socioeconomic and HIV status 
characteristics of HIV infected, pregnant women enrolled into the study. 
Variable 
 
Total population 
N=494 
Study sites 
Sarris 111 (22.5) 
Kolfe 96 (19.4) 
Meshualekiya 70 (14.2) 
Kirkos 59 (11.9) 
Sheromeda 58 (11.7) 
Gulele 51 (10.3) 
Bole 49 (9.2) 
Age (years)  
Median (IQR) 28 (25-31) 
18-24 years 110 (22.3) 
25-29 years 202 (40.9) 
≥30 years 182 (36.8) 
Marital Status 
Single 55 (11.1) 
Married, Committed, Co-habitating 414 (83.8) 
Divorced, separated, widowed 25 (5.1) 
Religion 
Orthodox Christian 408 (82.6) 
Muslim 48 (9.7) 
Protestant or Catholic Christian 38 (7.7) 
Ethnic tribe 
Oromo 136 (27.5) 
Amhara 240 (48.6) 
Gurage 57 (11.5) 
Tigre 37 (7.5) 
Wolyata 11 (2.2) 
Other 13 (2.6) 
Highest Educational level 
No school degree 86 (17.4) 
Primary 96 (19.4) 
(post) Secondary 295 (59.7) 
No information 17 (3.5) 
Values are provided for numbers (%), or medians (IQR) for continuous variables 
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Variable 
 
Total population 
N=494 
Current Occupation 
House wife 239 (48.4) 
Private employee 108 (21.9) 
Daily labourer 49 (9.9) 
Government employee 35 (7.1) 
House maid 36 (7.3) 
Commercial sex worker 7 (1.4) 
Other 20 (4.1) 
Monthly family income 
(Ethiopian Birr*)  
median (IQR) 1000 (500-2000) 
0-500 127 (25.7) 
501-1500 190 (38.5) 
1501-2500 93 (18.8) 
Values are provided for numbers (%), or medians (IQR) for continuous variables; * 1 US Dollar= 21.55 Ethiopian Birr 
(1000 Ethiopian Birr =46.41 USD) 
3.3 HIV related characteristics and Gestational age during enrolment 
Approximately half of the participants were in their third trimester when they were recruited in 
to the study. HIV infection was known before pregnancy among 263 (53.2%) women and HIV 
was diagnosed in 223 (45.1%) women during the current pregnancy Table 5.   
A large proportion of the pregnant mothers initiated ART during current pregnancy, and only 
3.1% initiated ART at or after delivery (Figure 2). Significant proportions of the mothers (91.1%) 
were either in WHO Stage I or II.  The median CD4 count was 387 cells/µL and 14.8 % had a last 
CD4 count <200 cells/µL Table 5. 
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Table 5: Gestational age during enrolment and HIV related characteristics of pregnant women 
enrolled into the study in selected Addis Ababa Health Centers, Ethiopia, 2015 
Variable 
 
Total population 
N=494 
Trimester entered into the study 
1st trimester 44 (8.9) 
2nd trimester 200 (40.5) 
3rd trimester 250 (50.6) 
Time of first HIV diagnosis 
Before current pregnancy 263 (53.2) 
During current pregnancy 223 (45.1) 
Not known 8 (1.6) 
Start of antiretroviral therapy 
Before current pregnancy 166 (33.6) 
During/after current 
pregnancy 
321 (65.0) 
Not known 7 (1.4) 
ART regimen 
TDF, 3TC, EFV 295 (60.6) 
ZDV, 3TC, NVP 83 (17.0) 
ZDV-mono therapy 37 (7.6) 
TDF, 3TC, NVP 35 (7.2) 
ZDV, 3TC, EFV 29 (6.0) 
WHO-Stage 
Stage 1/2 450 (91.1) 
Stage 3/4 44 (8.9) 
Last CD4 count (cells/µL) 
Median (IQR) 387 (261-536) 
<200 cells/µL 73 (14.8) 
200-<350 cells/µL 135 (27.3) 
≥350 cells/µL 268 (54.3) 
Missing data 18 (3.6) 
Values are provided for numbers (%) 
 
3.4 Maternal ART/PMTCT initiation and adherence 
ART was initiated during or after the pregnancy in 321 of women, of those 94 (29.3%) were 
known HIV positive before the current pregnancy but still ART naïve, 220 (68.5%) women were 
HIV diagnosed during this pregnancy and for 7 women the data of HIV diagnosis was not known. 
In 166 women ART was already initiated before the current pregnancy. Most women received 
fixed dose combination of tenofovir, lamivudine and efavirenz, and 37 women still received 
zidovudine monotherapy following previous Option A procedures prior to the national transition 
into Option B+ policies (Table 5). The median time of ART initiation before delivery in women 
starting treatment during pregnancy was 17.4 weeks (IQR 11.7-23.9). Antiretroviral PMTCT 
coverage before delivery was critical in 19 (5.9%) women who had either no ART at delivery 
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(N=10) or very recently ART initiation (N=9) less than four weeks before delivery. In addition, 56 
(17.4%) women initiated ART between 4 to 12 weeks before delivery accounting for suboptimal 
antiretroviral PMTCT coverage (Figure 4). Very late or late ART initiation in these 75 women was 
due to either late HIV diagnosis in 46 (61.3%), but due to delayed ART initiation despite known 
HIV diagnosis in 29 (38.7%) cases. The median time between HIV diagnosis and start of ART in 
women who were HIV diagnosed during pregnancy was 1.3 weeks (IQR 0-4.3), with 25.9% 
undergoing treatment initiation at the same day of HIV diagnosis, cumulatively 46.4 % started 
within one week and 74.1% within one month after diagnosis (Figure 5). Very late HIV diagnosis 
with less than 4 weeks before delivery or at the time of delivery was done in 6 (2.7%) and 3 
(1.4%) women, respectively (Figure 3). 
Figure 3: Weeks of HIV diagnosis before delivery in HIV Infected, pregnant women who 
received first HIV diagnosis during pregnancy 
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Figure 4: Weeks of ART initiation before delivery in HIV infected, pregnant women who 
initiated ART during pregnancy 
 
Figure 5: Weeks between HIV diagnosis and ART initiation in HIV infected, pregnant women 
who received first HIV diagnosis during pregnancy and initiated ART during pregnancy 
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3.5 Adherence and Risk factors associated with overall poor antiretroviral 
treatment adherence adjusted by study sites  
Overall self-reported antiretroviral treatment adherence was graded as good in 41.3% and poor 
in 17.3% of women, and adherence was comparable between women who had started ART 
during pregnancy or were on ART already before pregnancy (Table 6).  In contrast, treatment 
adherence was significantly better before delivery as compared to post-delivery (good 
adherence: 60.8% versus 50.5%, p= p<0.001; poor adherence: 7.0% versus 12.5%, p=0.002).   
Table 6: Treatment adherence (overall, before and after delivery) in HIV infected pregnant 
women for the total population and stratified by ART initiation before or during the current 
pregnancy.  
 
Variable 
Total 
population 
N=494 
ART initiation 
during/after 
pregnancy  
N=321* 
ART initiation 
before 
pregnancy 
N=166* 
ART adherence until delivery    
− good 296 (60.8) 200 (62.3) 96 (57.8) 
− moderate 92 (18.9) 57 (17.8) 35 (21.1) 
− poor 34 (7.0) 24 (7.5) 10 (6.0) 
− missing information 65 (13.3) 40 (12.5) 25 (15.1) 
ART adherence after delivery until Week- 6    
− good 246 (50.5) 168 (52.3) 78 (47.0) 
− moderate 116 (23.8) 73 (22.7) 43 (25.9) 
− poor 61 (12.5) 41 (12.8) 20 (12.0) 
− missing information 64 (13.1) 39 (12.2) 25 (15.1) 
Overall ART adherence    
− good 201 (41.3) 138 (43.0) 63 (38.0) 
− moderate 138 (28.3) 88 (27.4) 50 (30.1) 
− poor 84 (17.3) 56 (17.5) 28 (16.9) 
− missing information 64 (13.1) 39 (12.2) 25 (15.1) 
Values are provided for numbers (%); * N=7 women missing information on ART initiation 
Study site adjusted risk factors associated with overall poor self-reported ART adherence are 
shown in Table 7. Socio-demographic factors significantly associated with poor treatment 
adherence included women who were divorced, separated or widowed (RR 2.2, 95% CI 1.3-3.8, 
p=0.004) and women who had access to low family income (RR 2.1, 95% CI 1.1-4.1, p=0.027), 
whereas age, religion, ethnicity, education, occupation, HIV diagnosis or ART initiation before or 
during pregnancy were not associated with poor adherence. In women starting ART during 
pregnancy poor treatment adherence was moderately associated with low CD4 counts <200 
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cells/µL (RR 1.7, 95% CI 1.0-3.0, p=0.49) and significantly associated with ART initiation during 
delivery (RR 2.5, 95% CI 1.1-5.6, p=0.028). No association was seen for WHO stages or if ART was 
immediately initiated within one week after HIV diagnosis. 
Table 7: Demographic, socioeconomic, HIV status and antiretroviral risk factors associated 
with overall poor antiretroviral treatment adherence adjusted by study sites 
  Poor ART adherence adjusted by study site 
Variable n/ N (%) PR (95% CI) p-value 
Age groups 
18-24 years 24/93 (25.8) 1 - 
25-29 years 32 /174 (18.4) 0.7 (0.4-1.1) 0.156 
≥30 years 27/156 (17.3) 0.7 (0.4-1.1) 0.112 
Marital 
status 
Married, committed, cohabitating 69/355 (19.4) 1 - 
Single 5/47 (10.6) 0.5 (0.2-1.3) 0.167 
Divorced, separated, widowed 9/21 (42.9) 2.2 (1.3-3.8) 0.004 
Religion 
Orthodox Christian 73/274 (21.0) 1 - 
Muslim 3/40 (7.5) 0.4 (0.1-1.1) 0.066 
Protestant or catholic Christian 7/36 (19.4) 0.9 (0.5-1.9) 0.822 
Ethnicity 
Oromo 28/119 (23.5) 1 - 
Amhara 42/201 (20.9) 0.9 (0.6-1.4) 0.639 
Gurage 7/52 (13.5) 0.6 (0.3-1.2) 0.150 
Tigre 4/32 (12.5) 0.5 (0.2-1.4) 0.205 
Wolyata 0/9 (0) - - 
Other 2/8 (20) 0.8 (0.2-3.1) 0.804 
Education 
(post) Secondary 52/256 (20.3) 1 - 
Primary 16/82 (19.5) 1.0 (0.6-1.6) 0.880 
No school degree 11/68 (16.2) 0.8 (0.4-1.4) 0.449 
Occupation 
House Wife 44/212 (20.8) 1 - 
Private Employee 12/90 (14.4) 0.7 (0.4-1.2) 0.212 
Daily Labourer 6/40 (15.0) 0.7 (0.3-1.6) 0.409 
Government Employee 8/30 (26.7) 1.3 (0.7-2.5) 0.434 
House maid 4/29 (13.8) 0.7 (0.3-1.7) 0.399 
Commercial Sex Worker 2/7 (28.6) 1.4 (0.4-4.6) 0.609 
Other 6/15 (40.0) 1.9 (1.0-3.8) 0.064 
Family 
income 
>2500 10/76 (13.2) 1 - 
1501-2500 19/80 (23.8) 1.8 (0.9-3.6) 0.098 
501-1500 25/162 (15.4) 1.2 (0.6-2.3) 0.638 
0-500 29/105 (27.6) 2.1 (1.1-4.1) 0.027 
HIV 
diagnosis 
During pregnancy 37/195 (19.0) 1 - 
Before pregnancy 44/224 (19.6) 1.0 (0.7-1.5) 0.863 
ART 
initiation 
During pregnancy 55/281 (19.6) 1 - 
Before pregnancy 28/141 (19.9) 1.0 (0.7-1.5) 0.934 
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Table 8: Demographic, socioeconomic, HIV status and antiretroviral risk factors 
associated with overall poor antiretroviral treatment adherence adjusted by study 
sites for only women starting ART during pregnancy 
 
3.6 Infant outcome and PMTCT procedures 
Infant outcome information, was either directly obtained during study visits or through active 
tracing, 435 (88.1%) infants were born alive, 10 (2.0%) were stillbirths at delivery, there were 7 
(1.4%) abortions or early intra-uterine fetal deaths, and for 42 (8.5%) infants no outcome 
information was obtainable. For infants born alive birth characteristics (gender, type of delivery, 
birth weight, 5-minutes Apgar score) are listed in Table 9. Four infants died during the post-natal 
period either due to respiratory distress, pneumonia or unknown reasons, for none of these 
infants HIV infection information was collected. Nevirapine prophylaxis was initiated in 98.6% of 
infants born alive, in 2 cases prophylaxis was not initiated due to early infant death or mother’s 
refusal, and in 4 infants previously referred to other health facilities no information was 
obtainable. Self-reported adherence to NVP prophylaxis was good in the majority of patients, 
however, adherence reported at Week 6 was better than adherence reported at Day 6 (good 
adherence: 80.9% versus 76.6%, p=0.028;  poor adherence: 3% versus 7.4%, p=0.003).   
 
 Poor ART adherence adjusted by study site 
Variable n/N (%) PR (95% CI) p-value 
WHO Stage 
Stage 1/2 53/269 (19.7) 1 - 
Stage 3/4 2/12 (16.7) 0.9 (0.2-3.2) 0.848 
CD4 count 
≥350 cells/µL 28/153 (18.3) 1 - 
200-<350 cells/µL 10/77 (13.0) 0.7 (0.4-1.4) 0.313 
<200 cell/µL 14/44 (31.8) 1.7 (1.0-3.0) 0.049 
ART start before 
delivery 
>12 weeks 35 /209 (16.8) 1 - 
8-12 weeks 7/27 (25.9) 1.6 (0.8-3.2) 0.205 
4-8 weeks 6/27 (22.2) 1.3 (0.6-2.8) 0.501 
<4 weeks 3/8 (37.5) 2.2 (0.9-5.6) 0.097 
at/after delivery 4/10 (40.0) 2.5 (1.1-5.6) 0.028 
ART initiation 
after HIV 
diagnosis 
≥1 weeks after HIV diagnosis 38/188 (20.2) 1  
<1 week after HIV diagnosis 15/89 (16.9) 0.8 (8.5-1.4) 0.512 
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Table 9: Infant outcome, Nevirapine (NVP) prophylaxis and adherence in infants born alive. 
Data includes tracing information for infants who continued PMTCT procedures outside the 
study sites.  
Variable Life-born infants (N=435) 
Gender 
Female 212 (8.7) 
Male 218 (50.1) 
No information 5 (1.2) 
Type of delivery 
Spontaneous vaginal delivery 388 (89.2) 
Assisted vaginal delivery (vacuum/forceps) 1 (0.2) 
Caesarean section 41 (9.4) 
No information 5 (1.2) 
Birth weight (g)  median (IQR) 3000 (2800-3500) 
Apgar score 5 
minutes 
Normal (7-10) 410 (98.2) 
Low (4-6) 1 (0.2) 
No information 7 (1.6) 
NVP prophylaxis 
Started  429 (98.6) 
Not started  2 (0.5) 
Missing information 4 (0.9) 
NVP adherence 
until Day 6 post-
partum 
Good 333 (76.6) 
Moderate 57 (13.1) 
Poor 32 (7.4) 
No information 13 (3.0) 
NVP adherence 
between Day 6 
and Week 6 
post-partum 
Good 352 (80.9) 
Moderate 53 (12.2) 
Poor  13 (3.0) 
No information 17 (3.9) 
Infant Outcome 
Not HIV infected 428 (98.4) 
HIV infected 3 (0.7) 
Early infant death 4 (0.9) 
Values are provided for numbers (%), or medians (IQR) for continuous variables 
 
3.7 Turnaround time for PCR analysis of Dry Blood Spots  
Dry blood spot (DBS) collection for early infants HIV diagnostics (EID) was performed after a 
medium duration of 6.7 weeks (range 3.4 to 74 weeks) following birth (Figure 6).  DBS collection 
by week categories after delivery (Figure 6) indicating that only 12.2% had blood collected 
within the recommended period of 4 to 6 weeks post-partum, cumulative 68.2% until week 8, 
and 77.5% until week 12 post-partum. Eighty-three (19.1%) infants had DBS collected later than 
12 weeks postpartum, 5% more than one year after delivery (Figure 6).   
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Figure 6:  Proportion of infants born alive who received Dry Blood Spots Collection (DBS) at 
health facilities for Early Infant Diagnosis (EID) by weeks after delivery 
 
The turnaround time between DBS collection and receipt of EID results at the health center was 
in median 4.1 weeks (range 0.4 to 30.9 weeks) Figure 7. Turnaround times by week categories 
(Figure 7) indicating that cumulatively for 41.4% of infant’s health centers had received EID 
results by week 4 and for 76.3% by week 8 after DBS collection. For 33 (7.6%) infants results 
were obtained later than 8 weeks after DBS collection (Figure 7).   
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Figure 7:  Proportion of infants born alive who received EID results at health facilities by 
weeks after DBS Collection 
 
The turnaround time between birth and receipt of EID was in median 11.3 weeks (range 6.7 to 
78 weeks), week categories are shown in Figure 8. HIV results were available for cumulative 
46.7% of infants within the first 12 weeks, and for 71.5% of infants within the first 24 weeks of 
life (Figure 8). 
Figure 8: Proportion of infants born alive and who received EID results at health facilities by 
weeks after delivery  
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For 54 (12.5%) infants results were available after 24 weeks, for 4.4% even after one year 
Figure8. Out of 424 infants with available EID results only 2 (0.5%) were HIV-DNA reactive. In 
both cases mothers were on triple ART, infants received NVP prophylaxis, had DBS sample 
collection around week 7 and EID results were available at 9 and 10 weeks postpartum resulting 
into initiation of antiretroviral treatment. The third HIV infected infant was born from a mother, 
who terminated PMTCT during pregnancy, had home delivery and later DBS-EID procedures 
performed elsewhere with results available following tracing information. Therefore the overall 
transmission rate of 435 infants born alive was 0.7%, however, for 10 infants no HIV results 
were available either due to early infant death or missing outcome information. 
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4. Discussion: 
In our prospective study of HIV infected, pregnant women and their new-born infants conducted 
at seven obstetric and PMTCT service delivering health facilities in Addis Ababa we observed a 
low HIV mother-to-child HIV transmission rate of 0.7% after a median 6.7 weeks indicating a 
high effectiveness of the current PMTCT procedures.   
Previous studies from Ethiopian studies have reported transmission rates between 8.2 % and 
9.5% in 2009 [102],  the same author reported retrospectively assessed transmission rates of 
14.3% by 2006, 14.9% by 2007 and 8.2% by 2009 [101 ]. Further retrospective analysis from the 
Gondar University Referral Hospital indicated 10% transmission between 2005 and 2011 [104] 
and from the Dil Chora Referral Hospital 15.7% between 2005 and 2013 [105].  
Our data therefore reflects the beneficial impact of the latest recommendations on maternal 
and infant antiretroviral prevention in Ethiopia, namely associated with the introduction of 
maternal triple ART regimens.  However, our study was conducted during the transition period 
from WHO 2010 to the 2013 Option B+ PMTCT procedures, and 7.6% of women still received 
the Option A regimen.  
First data from the PROMISE study conducted in India, Malawi, South Africa, Tanzania, Uganda, 
Zambia and Zimbabwe reported similar transmission rates among women receiving triple drug 
regimens of 0.5% and 0.6% as compared to 1.8% among those receiving the Option A regimen 
[109]. 
The uptake of PMTCT procedures was very good in our study and only 2 women actively 
rejected procedures during pregnancy, in one this resulted into infant HIV transmission, and 3 
after birth. Adding 19 further cases of lost to follow-up despite repeated tracing attempts, we 
concluded our study with a 4.9% loss of follow-up which is less then reported in other studies 
[111]. 
The majority of women in our study were HIV diagnosed and started on ART during pregnancy 
with a median duration of 1.3 weeks between HIV diagnosis and ART initiation, 46.4% of women 
starting treatment within one week after diagnosis. The immediate initiation or ART at the time 
of HIV diagnosis (test and treat) as recommended within the Option B+ procedures is 
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controversially debated as there is concern on sustained treatment adherence.  In fact loss of 
treatment retention was reported to be higher in women starting on Option B+ as compared to 
those who were already on ART based on clinical and immunological criteria [111,112]. 
In our analysis we did not observe differences in self-reported treatment adherence in women 
who started ART within one week of HIV diagnosis as compared to those with later ART 
initiation, or in women who started ART during pregnancy as compared to those who were 
already on ART prior to pregnancy.  As very late (less than 4 weeks prior to delivery) or late (less 
than 12 weeks prior to delivery) treatment initiation was noted in 75 women and due to delayed 
ART initiation despite known HIV infection in 38.7% of these cases , test and treat procedures 
might have avoided this deficiency.  
The threshold duration of antenatal ART required for maximal PMTCT benefit is however 
unclear. The European Collaborative Study showed that 93.4% of women receiving NVP 
containing ART achieved viral suppression by 15 weeks [113].  A study of South African women 
initiating ART during pregnancy demonstrated that each additional week of treatment reduced 
the odds of perinatal HIV transmission by 8% [114], and the French Perinatal Cohort showed a 
reduction by 6% [115].  A retrospective cohort analysis of pregnant HIV-infected women in 
Zambia indicated that the optimal time of ART initiation should be in minimum 4 weeks but 
preferably 13 weeks prior to delivery [116].  
The assessment of self-reported antiretroviral treatment adherence is often considered to be 
less reliable mainly leading to underestimation of adherence deficiency [123]. 
Nevertheless, in our study a substantial proportion of women admitted poor or moderate 
treatment adherence (overall 28.3% and 17.3%, respectively) which apparently did not lead to 
high mother-to-child transmission rates, however, may raise concern on treatment durability 
and development of drug resistance as reported in pregnant women from South Africa [117] 
and Malawi [118].  
Evidence for decreased post-partum treatment adherence was also seen in our analysis, as the 
proportion of women with self-reported poor adherence was significantly higher prior to 
delivery as compared to post-partum treatment adherence. In addition, poor self-reported 
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adherence was significantly associated with women who started ART very late during the 
perinatal period, indicating that enforced adherence counselling after delivery is especially 
needed in these women. Other risk factors associated with poor treatment adherence were low 
CD4 counts, women who were separated, divorced or widowed, and women with very limited 
financial resources. Severe economic constraints represents most probably the most important 
risk factor in our population, which is affiliated with lack of transportation money to the health 
care facilities or lack of time to be spend for personal health care instead of generating income.  
In our study financial compensation for study visits were not provided as visits were based on 
the routine national antenatal and post-partum clinic appointments, however, financial support 
by health facilities was occasionally provided to those most in need. Interventions packages to 
increase the up-take and adherence to ART in Africa, including enforced patients counselling on 
HIV surrogate marker such as CD4 counts and strategies to meet economic challenges, are 
currently investigated in cluster-randomized trials such as the PopART Study (HPTN 071) [119]. 
Infant prophylactic NVP exposure in our study was very good and almost all infants started and 
complete treatments, possibly attributing to the low mother-to-child transmission rate 
observed. Self-reported adherence to NVP prophylaxis was better after one week as compared 
to the first six days following birth, possibly reflecting initial challenges to administer the NVP 
syrup appropriately.   
In contrast the analysis of EID procedures in our study revealed major challenges. Although the 
time of infant dry blood sample collection (median 6.7 weeks after birth) and turnaround time 
EID results after DBS collection (median 4.1 weeks) was relatively reasonable, however not 
meeting the targeted 4-6 weeks for sample collection and 2 weeks turnaround time for EID 
results by guidelines, only 4.8% of EID results were available within the recommended two-
months period following birth, and cumulatively 46.6% of EID results were available at the 
health facilities within three months. In a substantial proportion of cases EID results were 
received at much later time-points (cumulatively 12.5% later than 24 weeks after birth). The fact 
that that all infants alive received DBS collections and had reported EID results is most probably 
biased by study related perseverance.  One of the major reasons for deficiencies in EID 
procedures was a stock out of reagents for EID testing at the centralized laboratory in Addis 
Ababa in 2013 which lasted for several months.  Similar challenges are known form other 
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African countries as reflected within the UNAIDS report [1] and recently reviewed [120,121]. 
Challenges related to centralized EID procedures and linkage might be overcome with the 
introduction of novel point-of-care HIV diagnostic systems, which enable EID procedures directly 
at the health facilities and turnaround times of about one hour [122]. 
 
4.1 Conclusion 
In conclusion our study demonstrated low mother-to-child HIV transmission rates in mothers 
who, for the majority, received triple ART during pregnancy associated with high coverage of 
infant NVP prophylactic treatment.  Limitations for the generalizability of our results are mainly 
study procedure related, including selection bias of women who attended ANC and leaving out 
possibly most at risk cases who do not reach offered services, tracing procedures which might 
have affected our good PMTCT retention rates, repeated treatment counselling beyond the 
usual routine procedures, and perseverance to receive EID results. Despite that antiretroviral 
PMTCT coverage led to low transmission rates our data supports concerns of suboptimal 
treatment adherence possibly associated with later virological failure and drug resistance 
development which especially needs to be addressed during the post-partum period. 
Centralized EID procedures are complicated by linkage and infrastructural challenges which 
could be overcome with the implementation of novel EID point-of-care systems.  
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